Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
DYNAMICS OF SUCCESSDesitin Company Profile
Founded 100 years ago in Hamburg
Independent, family-owned, profitable company, based in Hamburg
About 300 employees in development, production, sales, medicine, marketing and administration
Established as a specialist in the fields of epilepsy and Parkinson’s disease
Addition of further CNS indications
General managersMartin Zentgraf MD, Karin Dethlefs and Christoph Steinschulte PhD
Our Heritage: Medium-sized, SpecializedPharmaceutical Company
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile2
Desitin Arzneimittel GmbH
Weg beim Jaeger 214
22335 Hamburg
Germany
Phone: +49 40 59101-0
Email: [email protected]
Our Headquarters and Place of Production
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile3
Our Strategy
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile4
Rx productsConcentration on special
in European countries with
successful partnerships,
licensing agreements
and own R&D
In-depth knowledge in epilepsy and Parkinson's disease
High medical expertise knowledge in dystonia, psychiatry, addiction, sleeping disorders
Success stories in scientific marketing of own and in-licensed Rx-products
Close networking with key opinion leaders
Relationships to patient organizations in several indications
Our Expertise: CNS Indications
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile5
Product and target-group specific sales strategies
Subsidiaries with sales teams in 11 European countries
Distribution partners in further 15 European countries
Our Expertise: Pan-European Distribution Network
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile6
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile7
DESITIN - A EUROPEAN CNS FORCE
Our Commercial Structure
KEY COUNTRIES(WITH OWN AFFILIATES)
Germany, Norway, Denmark, Sweden,
Switzerland, Czech Republic, Slovakia,Romania, U. K., Estonia, Moldova
PARTNER COUNTRIES(WITH LOCAL DISTRIBUTORS)
Austria, Belgium, Croatia, Finland,France, Hungary, Iceland, Netherlands,
Portugal, Spain, Turkey
8
Current Main Partner in Pan-EU Network
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile
France Spain Portugal Netherlands Belgium Finland Austria Croatia Hungary Iceland
Long experience in development ofproducts with different application forms
In-house production of pharmaceuticalproducts
Strong regulatory know-how forEuropean markets
Our Expertise: Fully-Integrated Pharmaceutical Company
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile9
Driving Growth by Own Developments
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile10
1982
Rectal tubes
(Diazepam DESITIN®
rectal tubes)
1996
First ready-to-useValproateinjection solution
(Orfiril® injection solution)
2006
First snab-tab Lamotriginefor optimal up-titration
(Lamotrigine DESITIN® quadro)
2011
First coated mini tabletsof Levetiracetam
(Levetiracetam DESITIN®)
2019
First Sultiame suspension
(Ospolot® Suspension)
1984
First sustained-
release
Carbamazepine
(Timonil® retard)
1998/1999
First sustained-release
mini tablets Valproate
(Orfiril® long)
2008
First modified-release
Oxcarbazepine
(Apydan® extent)
2016
First parkinson
combination therapy
in one tablet blister
(PramiDopa®)
2019
First Zonisamide
suspension
(Zonisol® Suspension)
Driving Growth with Marketing Licences
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile11
1993
Lamotrigine(Lamictal®)
(DE)
1998
Beta-Interferon 1a(Rebif®)
(DE)
2010
Naltrexone(Adepend®)
(DE)
2012
5-Aminolevulinic acid(Ameluz®)
(DK, NO, SE)
1995
DEC(Almirid®)
(DE)
2001
Paroxetinemesylate
(Euplix®) (DE)
Oxcarbazepine(Timox®) (DE)
2007
Naltrexone(Naltrexon HCI aop)
(DE)
2008
Stiripentol(Diacomit®)
(DE, DK, FI, NO, SE,
CZ, RO, SK)
2011
Tetrabenazine(Tetmodis®)
(DE)
2016
Riluzole liquid(Teglutik®)
(DE)
2017
Apomorphine(Apomorphine
Archimedes)
(DE)
2007
Piribedil (CLARIUM®)
(DE)
Botulinum Toxin A (Xeomin®)
(DK, NO, CZ, RO, SK)
Total Turnover in millions of EUR (Business Year: Oct 1st to Sept 30th)
Our Performance at a Glance
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile12
INTERNATIONAL
GERMANY
0
20
40
60
80
100
1200
7/0
8
09/1
0
11/1
2
13/1
4
15/1
6
17/1
8
18/1
9
mill
ion €
Our Share of Sales by Regions
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile13
Fiscal Year 2018/19Total Turnover: 109 million €
GERMANY
NORTHERN EUROPE
WESTERN EUROPE
EASTERN EUROPE
ROW
59%
12%
12%
12%5%
Our Share of Sales by Therapeutic Areas
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile14
Fiscal Year 2018/19Total Turnover: 109 million €
65%
25%
5%3%
2%
CNS Products: > 90 %
EPILEPSY = 65%
MOVEMENT DISORDERS = 25%
OTHER INDICATIONS = 10%
Our Production Output
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile15
1 Billionsemi-finished goods
FINISHED GOODS
IN HOUSE PRODUCTIONS
SUBCONTRACTED
70%
30%
Orphan Drugs
in all Indications
DYNAMICS OF SUCCESS I Desitin Company Profile16
NEUROLOGY PSYCHIATRY DERMATOLOGYOPHTHAL-
MOLOGY
ENT: EAR,
NOSE,
THROAT
FURTHER
INDICATIONS
Established Branded
Pharmaceuticals
New Therapeutic Entities
Pharmaceuticals with
Unique Application
Pediatric Drugs
OTX Products
for RO, CZ and SK
Late Stage Clinical
Projects (Phase IIb or III)
New Medical Devices
Ac
qu
isit
ion
In-L
ice
ns
ing
Deal Type
Co
-Pro
mo
tio
n / -
Ma
rke
tin
g
Our Passion for Partnerships
We are looking for
products in Europe and for
the following indications
15.01.2020
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile17
CompleteComplete
CANDIDATE INDICATION PHASE I/PK PHASE II PHASE III MAA MARKET
DST-061
i.m.
DST-108/9
buccal
DST-070
oral liquid
DST-071
oral liquid
DST-096
oral solid
DST-100 medical device
Epilepsy
Epilepsy
Epilepsy
Epilepsy
ObstructiveSleep Apnea
Parkinson‘s
Disease
DST-110
oral solidEpilepsy
DST-112
liquidEpilepsy
2019
DST-115
liquid
Our Development Pipeline
DST-111
liquidMRSA
Eradication
Complete
Ongoing
Complete
Ongoing
Ongoing
Ongoing
Ongoing
Ongoing
Ongoing
Complete 2019
2022
2024
2020
2021
2025
2022
2022
2028
Ongoing
Epilepsy
Policy of open books: complete transparencyin activities and figures
Passion for close co-operations
High flexibility of a privately held independent company
Fast decision-making procedures
Share of knowledge and experience
Our Strong Commitment in Partnering
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile18
DYNAMICS OF SUCCESSDesitin Company Profile
Backup
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile20
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile21
15%
6%
24%
3%
18%
10%
18%
9%
1%
31%
Germany Denmark Norway Sweden Switzerland Czech Republic Slovakia Romania United Kingdom Estonia
Source: IMS MIDAS international data, volume SU 2018, N03A Antiepileptics without substances Gabapentin & Pregabalin
Desitin Epilepsy Market Shares (Key Countries)Volume 2018 (Standard Units)
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile22
33%
11%
98%
12%
37%
17%23%
9%
2%
64%
Germany Denmark Norway Sweden Switzerland Czech Republic Slovakia Romania United Kingdom Estonia
Source: IMS MIDAS international data, volume SU 2018, substance Valproic Acid
Desitin Valproate (Orfiril® long) Market Shares (Key Countries) Volume 2018 (Standard Units)
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile23
44%
54%
36%
9%
Germany Denmark Switzerland Estonia
Source: IMS MIDAS international data, volume SU 2018, substance Oxcarbazepine
Desitin OXC (Apydan® (extent)) Market Shares (Key Countries) Volume 2018 (Standard Units)
15.01.202024 DYNAMICS OF SUCCESS I Desitin Company Profile
N3A
VPA
SWITZERLAND
No. 9
No. 3
No. 1
No. 2
No. 5
No. 3
No. 2
No. 1No. 12
No. 5
No. 1
No. 1
No. 1
No. 1
No. 2
No. 3 No. 2
No. 2
No. 5
No. 3
U.K.
DENMARK
NORWAY
SWEDEN
GERMANY
ESTONIA
CZECH REP.
SLOVAKIA
ROMANIA
Source: IMS MIDAS international data, volume SU 2018, N03A Antiepileptics without substances Gabapentin & Pregabalin
Our Market Position
Market shares epilepsy in unitsN3A / VPA-Market
Our Leading Products‘ Availability
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile25
Active PharmaceuticalIngredient (API)(FY 2018/19: approx. 142 t)
VALPROATE SODIUM,
1st line Antiepileptic in various presentations
CARBAMAZEPINE,
1st line Antiepileptic
OXCARBAZEPINE,
1st line Antiepileptic
LEVETIRACETAM,
1st line Antiepileptic
VPA(109 t)
CBZ(13 t)
OXC(12 t)
LEV(8 t)
Total Turnover in millions of EUR (Business Year: Oct 1st to Sept 30th)
Performance at a Glance
15.01.2020DYNAMICS OF SUCCESS I Desitin Company Profile26
0
20
40
60
80
100
120
08/0
9
09/1
0
10/1
1
11/1
2
12/1
3
13/1
4
14/1
5
15/1
6
16/1
7
17/1
8
18/1
9
mill
ion €